Evercore ISI raised the firm’s price target on Azenta (AZTA) to $50 from $48 and keeps an In Line rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and Diagnostics, the analyst argues that FY25 guides from the life science tools group are likely to be conservative on China and Pharma, while in MedTech the firm contends that “healthy” utilization trends and a margin expansion thesis support the group.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZTA:
- Azenta upgraded to Overweight, named new ‘Best Idea’ at Stephens
- Azenta, Inc. Navigates Global Data Protection Laws Amid Business Risks
- Closing Bell Movers: Keysight up 9% after Q4 earnings beat
- Flex to replace Azenta in S&P 400 at open on 11/25
- Azenta to replace Envestnet in S&P 600 at open on 11/25